Skip to main content
Journal cover image

Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma.

Publication ,  Journal Article
Chang, H-H; Hsieh, K-Y; Yeh, C-H; Tu, Y-P; Sheu, F
Published in: Int Immunopharmacol
February 2010

FVE is a documented immunomodulatory protein purified from Enoki mushroom (Flammulina velutipes) and known as an activator for human T lymphocytes. This present study was aimed to investigate the anti-tumor effect and the related mechanisms of oral administration of FVE using a murine hepatoma model. Oral administration of FVE (10mg/kg) significantly increased the life span and inhibited the tumor size of BNL 1MEA.7R.1 (BNL) hepatoma-bearing mice. Tumor-bearing mice receiving oral FVE treatment had the highest tumoricidal capacity of peritoneal macrophages and tumor-specific splenocytes against BNL hepatoma cells. In addition, in vivo neutralization of interferon-gamma (IFN-gamma) demonstrated a significant decrease of FVE-induced anti-tumor effect (P<0.05). The expression levels of major histocompatibility complex (MHC) class I and II molecules and costimulatory molecule CD80 on peripheral blood mononuclear cells obtained from the FVE-treated mice were upregulated as compared with those of the PBS-treated mice. Furthermore, immunohistochemical staining showed a strong inhibition of tumor growth and angiogenesis in hepatoma tissues after oral administration of FVE. Taken together, oral administration of FVE displayed anti-tumor activity through activating both innate and adaptive immunity of the host to prime a cytotoxic immune response and IFN-gamma played a key role in the anti-tumor efficacy of FVE.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int Immunopharmacol

DOI

EISSN

1878-1705

Publication Date

February 2010

Volume

10

Issue

2

Start / End Page

239 / 246

Location

Netherlands

Related Subject Headings

  • Spleen
  • Neovascularization, Pathologic
  • Mice, Inbred BALB C
  • Mice
  • Macrophages, Peritoneal
  • Liver Neoplasms
  • Leukocytes, Mononuclear
  • Interferon-gamma
  • Immunology
  • Immunologic Factors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chang, H.-H., Hsieh, K.-Y., Yeh, C.-H., Tu, Y.-P., & Sheu, F. (2010). Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma. Int Immunopharmacol, 10(2), 239–246. https://doi.org/10.1016/j.intimp.2009.10.017
Chang, Hui-Hsin, Kuang-Yang Hsieh, Chen-Hao Yeh, Yuan-Ping Tu, and Fuu Sheu. “Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma.Int Immunopharmacol 10, no. 2 (February 2010): 239–46. https://doi.org/10.1016/j.intimp.2009.10.017.
Chang, Hui-Hsin, et al. “Oral administration of an Enoki mushroom protein FVE activates innate and adaptive immunity and induces anti-tumor activity against murine hepatocellular carcinoma.Int Immunopharmacol, vol. 10, no. 2, Feb. 2010, pp. 239–46. Pubmed, doi:10.1016/j.intimp.2009.10.017.
Journal cover image

Published In

Int Immunopharmacol

DOI

EISSN

1878-1705

Publication Date

February 2010

Volume

10

Issue

2

Start / End Page

239 / 246

Location

Netherlands

Related Subject Headings

  • Spleen
  • Neovascularization, Pathologic
  • Mice, Inbred BALB C
  • Mice
  • Macrophages, Peritoneal
  • Liver Neoplasms
  • Leukocytes, Mononuclear
  • Interferon-gamma
  • Immunology
  • Immunologic Factors